Litigation Details for Purdue Pharma L.P. (Bankr. S.D.N.Y. 2019)

Purdue Pharma L.P. (Bankr. S.D.N.Y. 2019)

Docket		Date Filed	2019-09-15
Court	United States Bankruptcy Court, S.D. New York	Date Terminated
Cause		Assigned To	Sean H. Lane
Jury Demand		Referred To
Parties	BAYARD, P.A.; KROLL RESTRUCTURING ADMINISTRATION LLC
Patents	10,004,819; 10,006,091; 10,011,659; 10,011,857; 10,017,712; 10,058,630; 10,114,022; 10,125,364; 10,300,010; 10,407,434; 4,000,895; 6,398,671; 6,488,963; 7,048,928; 7,423,050; 7,658,945; 7,777,050; 7,897,050; 8,003,762; 8,080,575; 8,134,000; 8,269,040; 8,313,778; 8,337,888; 8,722,684; 9,023,391; 9,060,976; 9,073,933; 9,090,815; 9,090,945; 9,193,757; 9,522,919; 9,700,050; 9,730,934
Attorneys	Corey William Roush; Jeffrey R. Gleit
Firms	Arnold & Porter Kaye Scholer LLP
Link to Docket	External link to docket

Biologic Drugs cited in Purdue Pharma L.P.

Details for Purdue Pharma L.P. (Bankr. S.D.N.Y. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-15				External link to document
2019-09-15	1463	Response to Motion	,412, as U.S. Patent Nos. 8,337,888 (the “’888 patent”); 9,060,976 (the “’976 patent”); and 9,034,376…certain of the Debtors’ patents, including U.S. Patent No. 9,693,961 (“the ’961 Patent”). Shortly after the… Patent 9,693,961 B2 A. Related Proceedings Patent Owner asserted the ’961 patent against…Response, Patent Owner contends that, “transitional” continuation patents such as the ’961 patent are not…before the Patent Trial and Appeal Board (the “PTAB”), seeking a determination that the ’961 patent was invalid	External link to document
2019-09-15	1592	Objection to Motion	other patents in suit – U.S. Patent Nos. 9,073,933 (“’933 Patent”) and 9,522,919 (“’919 Patent”). These…of one of the Debtors’ patents, U.S. Patent No. 9,693,961 B2 (the “’961 Patent”). Collegium’s Response…’961 Patent — the subject of the PTAB Action — is just one of the patents in suit in the Patent Litigation…Action”) before the United States Patent and Trademark Office’s Patent Trial and Appeal Board (the “PTAB…These patents are not related to the ’961 Patent — they have different specifications, different records	External link to document
2019-09-15	2247	Exhibit 15	U.S.P.N.6,488,963) … listable patents may be granted, as issuance of a patent, claim scope, and patent expiration cannot… based upon a pending patent application. • All patents above are also listed in the … noted below - that name was rejected by the Patent and Trademark Office. In order to maintain brand…application for T ARGIN was rejected by the United States Patent and Trademark Office based on similarity	External link to document
2019-09-15	357	Schedules	ATTN: GENERAL COUNSEL U.S. PAT. NO. 7,658,945 DATED MARCH …relating to patent litigation Undetermined Nature of claim: Patent Litigation…relating to patent litigation Undetermined Nature of claim: Patent Litigation…relating to patent litigation Undetermined Nature of claim: Patent Litigation …relating to patent litigation Undetermined Nature of claim: Patent Litigation	External link to document
2019-09-15	382	Schedules	ATTN: GENERAL COUNSEL U.S. PAT. NO. 7,658,945 DATED MARCH … (Where available) 60. Patents, copyrights, trademarks, and trade secrets … (Where available) 60. Patents, copyrights, trademarks, and trade secrets … WYOMING, DE 2. 38 AMENDMENT NO. 1 TO THE PATENT 103988	External link to document

Purdue Pharma L.P. Bankruptcy and Litigation: A Comprehensive Summary and Analysis

Introduction

The bankruptcy case of Purdue Pharma L.P., Case No. 19-23649, is one of the most significant and contentious bankruptcy proceedings in recent history, involving complex legal issues, massive financial stakes, and profound social implications. Here, we delve into the key aspects of this case, including its background, procedural history, and the landmark Supreme Court decision.

Background

Purdue Pharma L.P., owned by the Sackler family since the 1950s, was at the center of the opioid crisis due to its marketing and production of OxyContin. Following an epidemic of opioid abuse and addiction, Purdue Pharma faced thousands of civil suits and pleaded guilty in 2007 to misstatements about OxyContin's safety[1][2][3].

Bankruptcy Filing

On September 15 and 16, 2019, Purdue Pharma L.P. and 23 affiliated debtors filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the Southern District of New York. This move was a response to the overwhelming financial burden from the opioid-related litigation[4].

Plan of Reorganization and Third-Party Releases

A critical component of Purdue Pharma's plan of reorganization was the inclusion of non-consensual third-party releases. The Sackler family, who had withdrawn approximately $11 billion from Purdue Pharma over the years, proposed to contribute up to $6 billion to the bankruptcy estate in exchange for a full release from all current and future claims related to the opioid crisis. This proposal was highly contentious, with many opioid victims, states, and other entities objecting to the release of the Sacklers from liability without their consent[1][2][3].

Procedural History

• Bankruptcy Court Approval: The initial plan of reorganization, including the third-party releases, was approved by Bankruptcy Judge Robert D. Drain despite objections from various parties[2].
• District Court Reversal: The District Court vacated the Bankruptcy Court's confirmation order, finding no basis for extinguishing claims against the Sacklers without the consent of the claimants[2].
• Second Circuit Reversal: On appeal, the Second Circuit reversed the District Court's decision and reinstated the confirmation of the modified plan, which included the increased $6 billion contribution from the Sacklers[2].
• Supreme Court Appeal: The U.S. Trustee appealed the Second Circuit’s decision to the Supreme Court, which granted a stay on the implementation of the Purdue plan while it considered the issue[2].

Supreme Court Decision

On June 27, 2024, the United States Supreme Court issued a landmark decision in the case, ruling that bankruptcy courts do not have the authority to approve non-consensual third-party releases. Here are the key points from the decision:

• Authority of Bankruptcy Courts: The Supreme Court held that the Bankruptcy Code does not permit bankruptcy courts to extinguish claims against third parties, like the Sacklers, without the consent of the affected claimants[2].
• Statutory Interpretation: The Court interpreted the Bankruptcy Code, particularly Section 1123(b)(6), and concluded that the catch-all clause does not allow bankruptcy courts broad authority to order any form of relief not expressly forbidden by the Code[2].
• Historical Context: The Court looked to the history of the Bankruptcy Code and its predecessors, emphasizing that an absolute shield from liability is only available to parties who offer up substantially all of their assets to creditors for distribution. The Sacklers, who retained significant wealth derived from Purdue, did not meet this criterion[2].

Justice Neil Gorsuch, writing for the majority, equated the release of third-party claims against the Sacklers to the type of clean slate a debtor receives at the culmination of its bankruptcy case, after a distribution of its assets has been made to its creditors. Since the Sacklers did not submit themselves to the comprehensive process of bankruptcy and retained billions of dollars, the Court held that the release was outside the scope of what may be included in a plan of reorganization[2].

Impact of the Decision

The Supreme Court's decision has significant implications for future bankruptcy cases involving non-consensual third-party releases. It sets a clear precedent that such releases are not permissible without the consent of the affected claimants, thereby protecting the rights of creditors and ensuring that non-debtors cannot avoid liability through bankruptcy proceedings.

Financial and Social Implications

The decision means that the Sackler family will not receive the blanket shield from liability they sought. This could lead to further litigation and potential financial liabilities for the Sacklers. For the opioid victims and other claimants, the decision is a victory in their pursuit of justice and compensation for the harm caused by Purdue Pharma's actions.

Legal Precedent

The Supreme Court's ruling in this case clarifies the limits of bankruptcy court authority and reinforces the principle that bankruptcy relief is designed for the benefit and protection of debtors who fully participate in the bankruptcy process. This precedent will guide future bankruptcy cases and ensure that non-debtors cannot exploit the bankruptcy system to avoid liability.

Quotes from Industry Experts

"The Supreme Court's decision is a significant victory for the rule of law and for the rights of creditors. It ensures that bankruptcy courts cannot be used as a tool to shield non-debtors from liability without their consent."[2]

Illustrative Statistics

• $11 Billion: The amount withdrawn by the Sackler family from Purdue Pharma over the years.
• $6 Billion: The amount the Sacklers agreed to contribute to the bankruptcy estate in exchange for the release.
• $40 Trillion: The estimated value of civil claims against Purdue Pharma.
• 2007: The year Purdue Pharma pleaded guilty to misstatements about OxyContin's safety.

Key Takeaways

• The Supreme Court ruled that bankruptcy courts cannot approve non-consensual third-party releases.
• The decision protects the rights of creditors and ensures that non-debtors cannot avoid liability through bankruptcy.
• The Sackler family will not receive a blanket shield from liability related to the opioid crisis.
• The ruling sets a clear precedent for future bankruptcy cases involving third-party releases.

FAQs

What was the main issue in the Purdue Pharma bankruptcy case?

The main issue was whether a bankruptcy court could approve non-consensual third-party releases, specifically releasing the Sackler family from liability related to the opioid crisis without the consent of the affected claimants.

Who are the Sacklers and what role did they play in the case?

The Sacklers are the family that owned Purdue Pharma. They sought a release from all current and future claims related to the opioid crisis in exchange for contributing up to $6 billion to the bankruptcy estate.

What was the Supreme Court's decision in the case?

The Supreme Court ruled that bankruptcy courts do not have the authority to approve non-consensual third-party releases, thereby denying the Sackler family the release they sought.

What are the implications of the Supreme Court's decision?

The decision sets a precedent that non-consensual third-party releases are not permissible, protecting the rights of creditors and ensuring that non-debtors cannot avoid liability through bankruptcy proceedings.

How much did the Sacklers withdraw from Purdue Pharma?

The Sackler family withdrew approximately $11 billion from Purdue Pharma over the years.

Cited Sources

1. Harrington v. Purdue Pharma L.P. and the Future of Nonconsensual Third-Party Releases in Bankruptcy - O'Melveny & Myers LLP
2. Supreme Court Rejects Non-Consensual Third-Party Releases in Purdue Pharma Bankruptcy - Chapman and Cutler LLP
3. IN RE: PURDUE PHARMA L.P. (2023) - FindLaw Caselaw
4. Purdue Pharma LP - Restructuring Administration Cases - Kroll Restructuring Administration
5. In Re: 19-23649-shl Purdue Pharma L.P. - United States Bankruptcy Court for the Southern District of New York

Last updated: 2025-01-14